Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Étude de l'efficacité et de l'innocuité du PF-06741086 chez des participants adultes et adolescents atteints d'hémophilie A sévère ou d'hémophilie B modérément sévère à sévère

23 juillet 2026 mis à jour par: Pfizer

Une étude ouverte chez l'adolescent et l'adulte sévère (activité du facteur de coagulation

Le traitement avec le PF-06741086 devrait démontrer un avantage cliniquement pertinent et/ou une contribution majeure aux soins des patients par rapport aux méthodes actuelles de traitement de l'hémophilie A ou B, car il fonctionne différemment des produits de remplacement de facteur et fonctionnera en présence d'inhibiteurs . Le potentiel d'une administration sous-cutanée (SC) une fois par semaine (QW) offre des options de traitement en l'absence d'accès vasculaire fiable, une commodité accrue et peut permettre une meilleure observance. Combinées, ces qualités devraient entraîner une réduction des épisodes hémorragiques.

Aperçu de l'étude

Statut

Complété

Les conditions

Intervention / Traitement

Type d'étude

Interventionnel

Inscription (Réel)

188

Phase

  • Phase 3

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Gauteng
      • Johannesburg, Gauteng, Afrique du Sud, 2193
        • Charlotte Maxeke Johannesburg Academic Hospital
      • Jeddah, Arabie Saoudite, 21589
        • King AbdulAziz University Hospital
      • Riyadh, Arabie Saoudite
        • King Faisal Specialist Hospital & Research Center
      • Sofia, Bulgarie, 1756
        • National Specialized Hospital for the Active Treatment of Hematological Diseases - EAD, Sofia
      • Stara Zagora, Bulgarie, 6003
        • UMHAT "Prof.Dr. Stoyan Kirkovich"
    • Ontario
      • Hamilton, Ontario, Canada, L8S 4K1
        • McMaster University
      • Hamilton, Ontario, Canada, L8S 4K1
        • McMaster Children's Hospital
      • Hamilton, Ontario, Canada, L8N 3Z5
        • McMaster University Medical Centre - Hamilton Health Sciences
      • Toronto, Ontario, Canada, M5G 1X8
        • The Hospital for Sick Children
      • Beijing, Chine, 100045
        • Beijing Children's Hospital, Capital Medical University
    • Guangdong
      • Guangzhou, Guangdong, Chine, 510515
        • Nanfang Hospital, Southern Medical University
    • Guizhou
      • Guiyang, Guizhou, Chine, 550004
        • The Affiliated Hospital of Guizhou Medical University
    • Jiangxi
      • Nanchang, Jiangxi, Chine, 306113
        • Jiangxi Provincial People's Hospital
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, Chine, 300020
        • Institute of Hematology, Chinese Academy of Medical Sciences
      • Daegu, Corée du Sud, 41944
        • Kyungpook National University Hospital
      • Seoul, Corée du Sud, 03722
        • Severance Hospital, Yonsei University Health System
      • Seoul, Corée du Sud, 05278
        • Kyung Hee University Hospital at Gangdong
      • Zagreb, Croatie, 10000
        • Klinicki bolnicki centar Zagreb
      • A Coruña, Espagne, 15006
        • Hospital Universitario A Coruna
      • Barcelona, Espagne, 08035
        • Hospital Universitario Vall d´Hebron
      • Madrid, Espagne, 28046
        • Hospital Universitario La Paz
      • Salamanca, Espagne, 37007
        • Hospital Universitario De Salamanca
      • Zaragoza, Espagne, 50009
        • Hospital Universitario Miguel Servet
      • Paris, France, 75015
        • Hôpital Necker Enfants malades
      • Hong Kong, Hong Kong
        • Queen Mary Hospital
      • Hong Kong, Hong Kong
        • Prince of Wales Hospital
    • Gujarat
      • Surat, Gujarat, Inde, 395002
        • Nirmal Hospital Pvt, Ltd
    • Maharashtra
      • Pune, Maharashtra, Inde, 411004
        • Sahyadri Super Speciality Hospital
      • Pune, Maharashtra, Inde, 411004
        • Sahyadri Clinical Research And Development Center
    • Tamil Nadu
      • Vellore, Tamil Nadu, Inde, 632004
        • Christian Medical College
      • Perugia, Italie, 06156
        • Università degli Studi di Perugia, Azienda Ospedaliera di Perugia, Ospedale Santa Maria della
    • Milan
      • Milan, Milan, Italie, 20122
        • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
    • RM
      • Roma, RM, Italie, 00161
        • Università degli Studi di Roma "Sapienza"-Policlinico Umberto I
      • Hiroshima, Japon, 734-8551
        • Hiroshima University Hospital
    • Aichi-ken
      • Nagoya, Aichi-ken, Japon, 466-8560
        • Nagoya University Hospital - Transfusion Medicine
    • Hokkaido
      • Sapporo, Hokkaido, Japon, 004-0041
        • Sapporo Tokushukai Hospital
    • Saitama
      • Iruma-gun, Saitama, Japon, 350-0495
        • Saitama Medical University Hospital
    • Nuevo León
      • Monterrey, Nuevo León, Mexique, 64460
        • Hospital Universitario "Dr Jose Eleuterio Gonzalez"
    • Yucatán
      • Mérida, Yucatán, Mexique, 97130
        • Centro Multidisciplinario para el Desarrollo Especializado de la Inv. Clínica en Yucatán, S.C.P.
      • Muscat, Oman, 123
        • Sultan Qaboos University Hospital
      • Samara, Russie, 443079
        • FGBOU VO "Samara State Medical University" of MoH of Russia
      • Belgrade, Serbie, 11000
        • Clinical Center of Serbia
      • Belgrade, Serbie, 11000
        • Institute for Mother and Child healthcare "Dr Vukan Cupic"
      • Kragujevac, Serbie, 34000
        • Clinical Center Kragujevac
      • Niš, Serbie, 18000
        • Clinical Center Niš
      • Taichung, Taïwan, 40705
        • Taichung Veterans General Hospital
    • Changhua County
      • Changhua, Changhua County, Taïwan, 500
        • Changhua Christian Hospital
      • Adana, Turquie (Türkiye), 01130
        • Acibadem Adana Hospital
      • Ankara, Turquie (Türkiye), 06230
        • Hacettepe University Medical Faculty
      • Ankara, Turquie (Türkiye), 06500
        • Gazi University Health Research and Practice Center Gazi Hospital
      • Antalya, Turquie (Türkiye), 07060
        • Akdeniz University Medical Faculty
      • Gaziantep, Turquie (Türkiye), 27310
        • Gaziantep University Sahinbey Research and Training Hospital
      • Istanbul, Turquie (Türkiye), 34093
        • Istanbul University Oncology Institute
      • Izmir, Turquie (Türkiye), 35040
        • Ege University Medical Faculty
      • Izmir, Turquie (Türkiye), 35210
        • Dr. Behcet Uz Child Diseases Surgery Education and Research Hospital
      • Kayseri, Turquie (Türkiye), 38039
        • Erciyes University Medical Faculty
      • Samsun, Turquie (Türkiye), 55280
        • Ondokuz Mayıs University Medical Faculty
      • Trabzon, Turquie (Türkiye), 61080
        • Karadeniz Technical University Medical Faculty
    • Florida
      • Tampa, Florida, États-Unis, 33612
        • USF Health Morsani Center for Advanced Healthcare
    • Iowa
      • Iowa City, Iowa, États-Unis, 52242
        • University of Iowa
    • New York
      • New Hyde Park, New York, États-Unis, 11040
        • Northwell Health HTC
    • Washington
      • Seattle, Washington, États-Unis, 98101
        • Washington Institute for Coagulation

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

12 ans à 74 ans (Enfant, Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

La description

Critère d'intégration

  • Participants avec un diagnostic d'hémophilie A sévère ou d'hémophilie B modérément sévère à sévère avec un poids minimum de 35 kg au moment du dépistage.
  • Participant ou représentant légalement autorisé, ou soignant du participant capable de donner un consentement éclairé signé (ou un consentement mineur, le cas échéant).

Les participants inscrits dans la cohorte non inhibitrice doivent également répondre aux critères suivants :

  • Aucun antécédent détectable ou documenté d'inhibiteurs
  • Participants sous prophylaxie de routine FVIII/FIX qui ont démontré au moins 80 % d'observance du schéma prophylactique programmé au cours des 6 mois précédant l'inscription et qui sont disposés à continuer à recevoir un traitement prophylactique de routine avec remplacement du FVIII/FIX pendant la phase d'observation.
  • Participants avec un régime de traitement à la demande avec ≥ 6 épisodes hémorragiques aigus (spontanés ou traumatiques) nécessitant une perfusion de facteur de coagulation au cours de la période de 6 mois précédant l'inscription et souhaitant continuer à recevoir un traitement à la demande pendant la phase d'observation.

Les participants inscrits dans la cohorte des inhibiteurs doivent également répondre aux critères suivants :

  • Documentation de l'inhibiteur actuel à titre élevé (≥5 UB/mL) ou de l'inhibiteur actuel à faible titre (<5 UB/mL) réfractaire au remplacement du FVIII ou du FIX et avec une récupération du FVIII ou du FIX < 60 % de la valeur attendue au cours des 6 mois précédant l'inscription dans la phase d'observation
  • Participants hémophiles A avec un régime de traitement à la demande avec ≥ 6 épisodes hémorragiques ou participants hémophiles B avec ≥ 4 épisodes hémorragiques (spontanés ou traumatiques) nécessitant un traitement avec un facteur de pontage au cours des 6 mois précédant l'inscription à la phase d'observation et souhaitant continuer à recevoir sur -demander un traitement pendant la phase d'observation.
  • Les participants qui ont documenté des inhibiteurs pendant la thérapie de remplacement de facteur mais qui ne répondent pas aux critères quantitatifs d'inhibiteur décrits dans la puce précédente au moment du dépistage (par exemple, participant avec un inhibiteur à titre élevé précédemment documenté (≥ 5 BU/mL) et dont l'état exclut une nouvelle provocation avec le remplacement du FVIII ou du FIX) peut être considérée comme éligible au cas par cas avec l'accord préalable du moniteur médical Pfizer
  • Les participants qui répondent aux critères de saignement indiqués ci-dessus et qui sont sous prophylaxie de routine (définie comme un traitement par injection intraveineuse de facteur de pontage pour prévenir les saignements) et qui ont démontré au moins 80 % d'observance du schéma prophylactique programmé au cours des 6 mois précédant l'inscription, peuvent être l'éligibilité est considérée au cas par cas avec discussion et accord du moniteur médical Pfizer.

Critère d'exclusion

  • Traitement antérieur ou actuel et/ou antécédents de maladies coronariennes, de thrombose veineuse ou artérielle ou de maladie ischémique
  • Intervention chirurgicale prévue connue au cours de la période d'étude prévue.
  • Anomalie hémostatique connue autre que l'hémophilie A ou B.
  • Fonction rénale ou hépatique anormale
  • Maladie hépatique ou biliaire instable actuelle
  • Paramètres hématologiques anormaux
  • Autre affection médicale ou psychiatrique aiguë ou chronique ou anomalie de laboratoire pouvant augmenter le risque associé à la participation à l'étude ou à l'administration du produit expérimental ou pouvant interférer avec l'interprétation des résultats de l'étude et, de l'avis de l'investigateur,
  • Prophylaxie de routine en cours avec un agent de dérivation ou une thérapie de remplacement non facteur de coagulation, ou tout traitement antérieur avec un produit de thérapie génique pour le traitement de l'hémophilie (les participants traités par prophylaxie utilisant des agents de dérivation ou qui ont déjà reçu un traitement avec des produits non facteurs peuvent être à considérer au cas par cas).
  • Traitement régulier et concomitant avec des médicaments immunomodulateurs

    - Utilisation continue ou planifiée de l'induction de la tolérance immunitaire pendant la phase d'observation ou la phase de traitement actif, ou prophylaxie par remplacement du FVIII ou du FIX à tout moment après le début du traitement avec intervention à l'étude pendant la phase de traitement actif

  • Exposition antérieure au PF 06741086 lors de la participation aux études B7841002 et B7841003.
  • Participation à d'autres études impliquant des médicaments expérimentaux ou des vaccins expérimentaux dans les 30 jours (ou tel que déterminé par les exigences locales) ou 5 demi-vies avant l'entrée à l'étude et/ou pendant la participation à l'étude.
  • Numération des cellules CD4 ≤ 200/uL si le virus de l'immunodéficience humaine (VIH) est positif
  • ECG de dépistage qui démontre des anomalies cliniquement pertinentes pouvant affecter la sécurité des participants ou l'interprétation des résultats de l'étude.
  • Les personnes présentant une hypersensibilité ou une réaction allergique aux protéines de hamster ou à d'autres composants de l'intervention à l'étude.
  • Les membres du personnel du site de l'investigateur directement impliqués dans la conduite de l'étude et les membres de leur famille, les membres du personnel du site autrement supervisés par l'investigateur ou les participants qui sont des employés de Pfizer, y compris les membres de leur famille, directement impliqués dans la conduite de l'étude.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: N / A
  • Modèle interventionnel: Affectation croisée
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: PF-06741086
Les participants seront affectés à un traitement avec PF-06741086 après une phase d'observation de 6 mois sur leur régime actuel d'hémophilie.
300 milligrammes (mg) dose de charge sous-cutanée (sc) suivie de 150 mg sq une fois par semaine (qw). 300 mg sc qw sont prescrits aux participants qui répondent aux critères d'escalade de dose.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Model-Based Annualized Bleeding Rate (ABR) of Treated Bleeding Events: Inhibitor Cohort (Participants With Prior OD Therapy at OP)
Délai: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
ABR is defined as number of bleeding episodes per year. ABR was calculated as number of bleeds requiring treatments/ (days on treatment period/365.25). If a participant did not complete a treatment period, days on treatment ended at last dosing date + 6 days. Treated bleed: If a bleed was treated with factor replacement or bypass agents within 48 hours of start of bleeding, regardless of the type of treatment (preventive, prophylaxis or OD medication). A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
Model-Based ABR of Treated Bleeding Events: Non-Inhibitor Cohort (Participants With Prior OD Therapy at OP)
Délai: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
ABR is defined as number of bleeding episodes per year. ABR was calculated as number of bleeds requiring treatments/ (days on treatment period/365.25). If a participant did not complete a treatment period, days on treatment ended at last dosing date + 6 days. Treated bleed: If a bleed was treated with factor replacement or bypass agents within 48 hours of start of bleeding, regardless of the type of treatment (preventive, prophylaxis or OD medication). A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
Model-Based ABR of Treated Bleeding Events: Non-Inhibitor Cohort (Participants With RP at OP)
Délai: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
ABR is defined as number of bleeding episodes per year. ABR was calculated as number of bleeds requiring treatments/ (days on treatment period/365.25). If a participant did not complete a treatment period, days on treatment ended at last dosing date + 6 days. Treated bleed: If a bleed was treated with factor replacement or bypass agents within 48 hours of start of bleeding, regardless of the type of treatment (preventive, prophylaxis or OD medication). A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
Number of Participants With Adverse Events (AEs): Inhibitor and Non-Inhibitor Cohort
Délai: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs included both serious AEs and all other AEs.
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
Number of Participants With Serious Adverse Events (SAEs): Inhibitor and Non-Inhibitor Cohort
Délai: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
AE: any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. SAE: any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; or that was considered as an important medical event.
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
Number of Participants With Thrombotic Events: Inhibitor and Non-Inhibitor Cohort
Délai: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
Thrombotic events are when a blood clot (thrombus) forms in a blood vessel in the arm, leg, lung, or head and can be life-threatening. A thrombus can occur in veins (venous thrombosis) or arteries (arterial thrombosis).
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
Number of Participants With Thrombotic Microangiopathy: Inhibitor and Non-Inhibitor Cohort
Délai: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
Thrombotic microangiopathy: pathological state where micro-vessels are occluded by platelet rich thrombi leading to thrombocytopenia (low platelets) and microangiopathic haemolytic anaemia (red blood cell destruction) and potential end organ damage.
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
Number of Participants With Disseminated Intravascular Coagulation/ Consumption Coagulopathy: Inhibitor and Non-Inhibitor Cohort
Délai: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
Disseminated intravascular coagulation is characterized by widespread clotting in small blood vessels, and consumption of platelets and clotting factors by the clots, leading to bleeding.
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
Number of Participants With Anti-drug Antibodies (ADA) and Neutralizing Antibodies (NAb) Against PF- 06741086: Inhibitor and Non-Inhibitor Cohort
Délai: During prophylaxis treatment in ATP (12 months)
ADA positive: A participant with >=1 treatment induced or treatment-boosted ADA response. NAb positive: An ADA positive participant with >=1 treatment induced or treatment boosted NAb response.
During prophylaxis treatment in ATP (12 months)
Number of Participants With Transient and Persistent ADA and NAb Against PF-06741086: Inhibitor and Non-Inhibitor Cohort
Délai: During prophylaxis treatment in ATP (12 months)
Persistent ADA: participant with treatment-induced or treatment-boosted ADA detected at 2 or more times during treatment including any follow-up, where first and last ADA positive samples separated by >=16 weeks. Transient ADA: treatment-induced or treatment-boosted ADA detected at only 1 time during treatment or follow-up. Persistent NAb: NAb-positive participant with first and last positive NAb samples detected >=16 weeks posttreatment, irrespective of any negative samples in between. Transient NAb: NAb-positive participant with (1) treatment-induced/treatment-boosted NAb sample detected at only 1 time posttreatment or (2) treatment-induced/treatment-boosted NAb samples detected at 2 or more times where first and last positive samples separated by <16 weeks, and participant's last sample was NAb or ADA negative.
During prophylaxis treatment in ATP (12 months)
Number of Participants With Injection Site Reactions (ISRs): Inhibitor and Non-Inhibitor Cohort
Délai: During prophylaxis treatment in ATP (12 months)
ISR included: injection site haematoma, injection site pain, injection site bruising, injection site erythema, injection site induration, injection site oedema, Injection site pruritus and Injection site swelling. ISR graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 where grade 1: tenderness with or without associated symptoms (warmth, erythema, itching), grade 2: pain, lipodystrophy, edema, phlebitis, grade 3: ulceration or necrosis, severe tissue damage, operative intervention indicated, grade 4: life-threatening consequences, urgent intervention indicated and grade 5: death. In this outcome measure only categories with non-zero values reported.
During prophylaxis treatment in ATP (12 months)
Number of Participants With Clinically Significant Changes in Physical Examinations: Inhibitor and Non-Inhibitor Cohort
Délai: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
Physical examination included assessments of the head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems. Height and weight were also measured and recorded. Clinical significance in physical examinations was determined by investigator.
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
Number of Participants With Clinically Significant Changes in Vital Signs: Inhibitor and Non-Inhibitor Cohort
Délai: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
Vital signs included temperature, pulse rate, respiratory rate, and blood pressure. Blood pressure and pulse rate were measured in a supine position using completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Respiratory rate was measured by observing and counting the respirations of the participant for 30 seconds and multiplied by 2. Clinical significance of vital signs was determined by investigator.
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters: Inhibitor and Non-Inhibitor Cohort
Délai: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
Hematology included: hemoglobin; leukocytes; neutrophils; and platelets. Chemistry included: potassium; aspartate aminotransferase; creatinine; alkaline phosphatase; total bilirubin; albumin; calcium corrected, estimated decreased; sodium; and calcium. Clinical significance of laboratory parameters was determined by investigator.
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
Number of Participants With Severe/ Systematic Hypersensitivity and Anaphylactic Reactions: Inhibitor and Non-Inhibitor Cohort
Délai: During prophylaxis treatment in ATP (12 months)
Systemic hypersensitivity is a complex immune response where the immune system reacts excessively to an antigen, often leading to severe allergic reactions, including widespread symptoms (which may affect multiple organs), such as rash, swelling of your face, lips, mouth, or tongue, trouble breathing, wheezing, dizziness, fainting, fast heartbeat, pounding in your chest or sweating. Anaphylaxis is a severe, potentially fatal, systemic allergic reaction that occurs suddenly after contact with an allergy causing substance.
During prophylaxis treatment in ATP (12 months)

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Model-Based ABR of Joint Bleeds: Inhibitor and Non-Inhibitor Cohort
Délai: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
ABR: number of bleeding episodes per year. ABR was calculated as number of bleeds requiring treatments/ (days on treatment period/365.25). If a participant did not complete a treatment period, days on treatment ended at last dosing date + 6 days. Joint bleed: bleeding episode characterized by rapid loss of range of motion as compared with baseline that was associated with any combination of the following: pain or an unusual sensation in the joint, palpable swelling, and warmth of the skin over the joint. A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
Model-Based ABR of Spontaneous Bleeds: Inhibitor and Non-Inhibitor Cohort
Délai: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
ABR: number of bleeding episodes per year. ABR was calculated as the number of bleeds requiring treatments/ (days on treatment period/365.25). If a participant did not complete a treatment period, the days on treatment ended at the last dosing date + 6 days. Spontaneous bleed: Bleeding for no apparent/known reason particularly into the joints, muscles, and soft tissues. A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
Model-Based ABR of Target Joint Bleeds: Inhibitor and Non-Inhibitor Cohort
Délai: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
ABR: number of bleeding episodes per year. ABR was calculated as number of bleeds requiring treatments/ (days on treatment period/365.25). If participant did not complete a treatment period, days on treatment ended at last dosing date + 6 days. Target joint: a major joint into which repeated bleeds occurred. Joint bleed: bleeding episode characterized by rapid loss of range of motion as compared with baseline that was associated with any combination of following: pain or unusual sensation in joint, palpable swelling, and warmth of the skin over joint. A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
Model-Based ABR of Total Bleeds: Inhibitor and Non-Inhibitor Cohort
Délai: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
ABR: number of bleeding episodes per year. ABR was calculated as number of bleeds requiring treatments/ (days on treatment period/365.25). If participant did not complete treatment period, days on treatment ended at last dosing date + 6 days. Treated bleed: If a bleed was treated with factor replacement or bypass agents within 48 hours of start of bleeding, regardless of the type of treatment (preventive, prophylaxis or on-demand medication). Untreated bleed: If a bleed was untreated with factor replacement or bypass agents within 48 hours of start of bleeding, regardless of the type of treatment (preventive, prophylaxis or on-demand medication), it was considered as an untreated bleed. Total bleeds: Treated bleeds + untreated bleeds. A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
Change From Baseline in Hemophilia Joint Health Score (HJHS) at Month 6: Non-Inhibitor Cohort
Délai: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
HJHS evaluated total joint score for 6 joints (left ankle, right ankle, left elbow, right elbow, left knee, right knee) and the global gait score. Joint total score per joint ranged from 0 to 20 (evaluated as: swelling [0-3], duration of swelling [0-1], muscle atrophy [0-2], crepitus on motion [0-2], flexion loss [0-3], extension loss [0-3], joint pain [0-2], and strength [0-4]). Global gait score ranged from 0 to 4 based on walking, stairs, running, and hopping on 1 leg. HJHS total score was sum of total joint score for 6 joints (0 to 120) and global gait score (0 to 4). The total HJHS score ranged from 0 to 124, where higher scores indicated worse joint health.
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Change From Baseline in HJHS at Month 6: Inhibitor Cohort
Délai: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
HJHS evaluated total joint score for 6 joints (left ankle, right ankle, left elbow, right elbow, left knee, right knee) and the global gait score. Joint total score per joint ranged from 0 to 20 (evaluated as: swelling [0-3], duration of swelling [0-1], muscle atrophy [0-2], crepitus on motion [0-2], flexion loss [0-3], extension loss [0-3], joint pain [0-2], and strength [0-4]). Global gait score ranged from 0 to 4 based on walking, stairs, running, and hopping on 1 leg. HJHS total score was sum of total joint score for 6 joints (0 to 120) and global gait score (0 to 4). The total HJHS score ranged from 0 to 124, where higher scores indicated worse joint health.
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Change From Baseline in Hemophilia Quality of Life Questionnaire for Adults (Haem-A-QoL) Total Score and Physical Health Domain at Month 6: Non-Inhibitor Cohort, Participants >=17 Years
Délai: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Haem-A-QoL assessed health-related quality of life (QoL) in adult participants (>=17 years of age) with hemophilia. It contained 46 items with 10 domains that assessed health in the following areas: physical health; feelings; view of self; sports and leisure; work and school; dealing with haemophilia; treatment; future; family planning; partnership and sexuality. All items were based on a 5-point Likert type scale (1= never, 2= rarely, 3= sometimes, 4= often, 5= all the time). Scoring was performed by averaging non-missing item responses for each domain, then each domain score was rescaled from 0 to 100, lower scores signified higher QoL. Total Haem-A-QoL score was averaged across the 46 items values and then rescaled from 0 to 100, lower Haem-A-QoL scores signified better QoL.
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Change From Baseline in Haem-A-QoL Total Score and Physical Health Domain at Month 6: Inhibitor Cohort, Participants >=17 Years
Délai: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Haem-A-QoL assessed health-related quality of life (QoL) in adult participants (>=17 years of age) with hemophilia. It contained 46 items with 10 domains that assessed health in the following areas: physical health; feelings; view of self; sports and leisure; work and school; dealing with haemophilia; treatment; future; family planning; partnership and sexuality. All items were based on a 5-point Likert type scale (1= never, 2= rarely, 3= sometimes, 4= often, 5= all the time). Scoring was performed by averaging non-missing item responses for each domain, then each domain score was rescaled from 0 to 100, lower scores signified higher QoL. Total Haem-A-QoL score was averaged across the 46 items values and then rescaled from 0 to 100, lower Haem-A-QoL scores signified better QoL.
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Change From Baseline in Hemophilia Quality of Life Questionnaire for Children (Haemo-QoL) Total Score at Month 6: Non-Inhibitor Cohort, Participants 12 to <17 Years
Délai: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Haemo-QoL assessed health-related QoL in adolescent participants (12 to <17 years of age) with hemophilia. It contains 12 items with 77 domains that assesses health in the following areas: physical health; feelings; attitude/view; family; friends; other people; sport and school; coping/dealing; treatment; perceived support; future and relationship. All items were based on 5-point Likert type scale (1= never, 2= rarely, 3= sometimes, 4= often, 5= all the time). Scoring was performed by averaging non-missing item responses for each domain, then rescaled from 0 to 100, lower scores signified higher QoL. Total Haem-A QoL score was averaged across the 77 items values and then rescaled from 0 to 100, lower Haemo-QoL scores signified better QoL.
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Change From Baseline in Haemo-QoL Total Score at Month 6: Inhibitor Cohort, Participants 12 to <17 Years
Délai: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Haemo-QoL assessed health-related QoL in adolescent participants (12 to <17 years of age) with hemophilia. It contains 12 items with 77 domains that assesses health in the following areas: physical health; feelings; attitude/view; family; friends; other people; sport and school; coping/dealing; treatment; perceived support; future and relationship. All items were based on 5-point Likert type scale (1= never, 2= rarely, 3= sometimes, 4= often, 5= all the time). Scoring was performed by averaging non-missing item responses for each domain, then rescaled from 0 to 100, lower scores signified higher QoL. Total Haem-A QoL score was averaged across the 77 items values and then rescaled from 0 to 100, lower Haemo-QoL scores signified better QoL.
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Change From Baseline in Hemophilia Activities List (HAL) Total Score at Month 6: Non-Inhibitor Cohort, Participants >=17 Years
Délai: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
The HAL was a multiple domain measure of the impact of hemophilia on functional abilities in adults (>=17 years of age). The 7 domains of this instrument contained 42 items in total, as follows: lying/sitting/kneeling/standing; lower (leg) functioning; upper (arm) functioning; transportation; self-care; household tasks; and sports/leisure. Items were rated on 6-point scale 1 (impossible) to 6 (never) that described difficulty due to hemophilia. HAL total score was sum of all items and scored 42 to 252, which were transformed to 0 - 100, where higher scores indicated better functional status.
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Change From Baseline in HAL Total Score at Month 6: Inhibitor Cohort, Participants >=17 Years
Délai: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
The HAL was a multiple domain measure of the impact of hemophilia on functional abilities in adults (>=17 years of age). The 7 domains of this instrument contained 42 items in total, as follows: lying/sitting/kneeling/standing; lower (leg) functioning; upper (arm) functioning; transportation; self-care; household tasks; and sports/leisure. Items were rated on 6-point scale 1 (impossible) to 6 (never) that described difficulty due to hemophilia. HAL total score was sum of all items and scored 42 to 252, which were transformed to 0 - 100, where higher scores indicated better functional status.
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Change From Baseline in Pediatric Hemophilia Activities List (pedHAL) Total Score at Month 6: Non-Inhibitor Cohort, Participants 12 to <17 Years
Délai: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
The pedHAL was a multiple domain measure of the impact of hemophilia on functional abilities in adolescents (12 to <17 years of age). The 7 domains of this instrument contained 53 items in total, as follows: sitting/kneeling/standing; functions of the legs; functions of the arms; use of transportation; self-care; household tasks; leisure activities and sports. Items were rated on 6-point scale 1 (impossible) to 6 (never) that described difficulty due to hemophilia. pedHAL total score was normalized in a range of 0 - 100, where higher scores indicated better functional status.
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Change From Baseline in pedHAL Total Score at Month 6: Inhibitor Cohort, Participants 12 to <17 Years
Délai: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
The pedHAL was a multiple domain measure of the impact of hemophilia on functional abilities in adolescents (12 to <17 years of age). The 7 domains of this instrument contained 53 items in total, as follows: sitting/kneeling/standing; functions of the legs; functions of the arms; use of transportation; self-care; household tasks; leisure activities and sports. Items were rated on 6-point scale 1 (impossible) to 6 (never) that described difficulty due to hemophilia. pedHAL total score was normalized in a range of 0 - 100, where higher scores indicated better functional status.
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Patient Global Impression of Change-Hemophilia (PGIC-H) at Month 6: Non-Inhibitor Cohort
Délai: Month 6
The PGIC-H was a single item assessment of the participant's overall impression of change in their life with hemophilia, on a 7-point scale (1= greatly improved to 7= greatly worsened, where lower scores indicated better improvement).
Month 6
PGIC-H at Month 6: Inhibitor Cohort
Délai: Month 6
The PGIC-H was a single item assessment of the participant's overall impression of change in their life with hemophilia, on a 7-point scale (1= greatly improved to 7= greatly worsened, where lower scores indicated better improvement).
Month 6
Change From Baseline in EuroQol 5 Dimensions 5 Level (EQ-5D-5L) Index and VAS Scores at Month 6: Non-Inhibitor Cohort
Délai: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
EQ-5D-5L consisted of participant completed questionnaire with 2 components: health state profile index and visual analogue scale (VAS). EQ-5D health state profile index has 5 domains (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), with 5 levels (1= no problems, 2= slight problems, 3= moderate problems, 4= severe problems, 5= extreme problems). Responses to 5 dimensions comprised health state index value. E.g. if a participant responds "no problems" for each 5 dimensions, then health state was coded as "11111" with predefined index value to it. EQ-5D-5L index score ranged from -0.594 to 1, United Kingdom look-up value was applied to all participants, higher scores indicated better health states. The EQ- VAS measured participant's self-rated health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state) by VAS, where higher scores indicated better heath states.
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Change From Baseline in EQ-5D-5L Index and VAS Scores at Month 6: Inhibitor Cohort
Délai: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
EQ-5D-5L consisted of participant completed questionnaire with 2 components: health state profile index and visual analogue scale (VAS). EQ-5D health state profile index has 5 domains (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), with 5 levels (1= no problems, 2= slight problems, 3= moderate problems, 4= severe problems, 5= extreme problems). Responses to 5 dimensions comprised health state index value. E.g. if a participant responds "no problems" for each 5 dimensions, then health state was coded as "11111" with predefined index value to it. EQ-5D-5L index score ranged from -0.594 to 1, United Kingdom look-up value was applied to all participants, higher scores indicated better health states. The EQ- VAS measured participant's self-rated health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state) by VAS, where higher scores indicated better heath states.
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Les enquêteurs

  • Directeur d'études: Pfizer CT.gov Call Center, Pfizer

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

9 mars 2020

Achèvement primaire (Réel)

29 avril 2025

Achèvement de l'étude (Réel)

29 avril 2025

Dates d'inscription aux études

Première soumission

2 mai 2019

Première soumission répondant aux critères de contrôle qualité

2 mai 2019

Première publication (Réel)

6 mai 2019

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

14 août 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

23 juillet 2026

Dernière vérification

1 juillet 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

Pfizer fournira un accès aux données individuelles des participants anonymisés et aux documents d'étude connexes (par ex. protocole, plan d'analyse statistique (PAS), rapport d'étude clinique (CSR)) à la demande de chercheurs qualifiés, et sous réserve de certains critères, conditions et exceptions. De plus amples détails sur les critères de partage des données de Pfizer et le processus de demande d'accès sont disponibles sur : https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner